Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Sirolimus on Ketamine's Antidepressant Effects
NCT02487485Phase 2Completed
- Sponsor
- Yale University
- Start
- Mar 2016
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in treatment-resistant depression (TRD), sponsored by Yale University. Started Mar 2016; status: completed.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT02487485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487485.